ValuEngine Lowers China Biologic Products (CBPO) to Strong Sell

ValuEngine lowered shares of China Biologic Products (NASDAQ:CBPO) from a sell rating to a strong sell rating in a research report sent to investors on Wednesday morning.

A number of other equities research analysts have also recently commented on CBPO. Jefferies Group reiterated a buy rating and set a $97.00 price target on shares of China Biologic Products in a report on Thursday, March 15th. Deutsche Bank set a $105.00 price target on shares of China Biologic Products and gave the company a buy rating in a report on Friday, March 2nd. TheStreet cut shares of China Biologic Products from a b- rating to a c+ rating in a report on Thursday, March 1st. BidaskClub upgraded shares of China Biologic Products from a sell rating to a hold rating in a report on Saturday, April 7th. Finally, Zacks Investment Research upgraded shares of China Biologic Products from a sell rating to a hold rating in a report on Monday, February 5th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the company. The stock has an average rating of Hold and a consensus price target of $101.00.

Shares of NASDAQ CBPO opened at $78.84 on Wednesday. China Biologic Products has a fifty-two week low of $71.85 and a fifty-two week high of $116.73. The company has a market cap of $2.61 billion, a price-to-earnings ratio of 15.93, a price-to-earnings-growth ratio of 1.17 and a beta of 1.47.

China Biologic Products (NASDAQ:CBPO) last announced its earnings results on Friday, May 4th. The biopharmaceutical company reported $1.21 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.22 by ($0.01). China Biologic Products had a net margin of 17.76% and a return on equity of 17.29%. The business had revenue of $112.50 million for the quarter, compared to the consensus estimate of $118.25 million. During the same period in the prior year, the business posted $1.32 EPS. China Biologic Products’s revenue for the quarter was up 23.0% on a year-over-year basis. equities research analysts expect that China Biologic Products will post 5.19 EPS for the current fiscal year.

Several large investors have recently bought and sold shares of CBPO. Wasatch Advisors Inc. grew its holdings in shares of China Biologic Products by 66.1% during the fourth quarter. Wasatch Advisors Inc. now owns 228,373 shares of the biopharmaceutical company’s stock valued at $17,989,000 after buying an additional 90,891 shares during the last quarter. SG Americas Securities LLC purchased a new stake in China Biologic Products in the fourth quarter worth approximately $117,000. California Public Employees Retirement System boosted its holdings in China Biologic Products by 9.4% in the fourth quarter. California Public Employees Retirement System now owns 48,964 shares of the biopharmaceutical company’s stock worth $3,857,000 after purchasing an additional 4,207 shares during the last quarter. First Trust Advisors LP boosted its holdings in China Biologic Products by 60.8% in the fourth quarter. First Trust Advisors LP now owns 30,251 shares of the biopharmaceutical company’s stock worth $2,383,000 after purchasing an additional 11,437 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in China Biologic Products by 5.5% in the fourth quarter. Bank of New York Mellon Corp now owns 804,495 shares of the biopharmaceutical company’s stock worth $63,370,000 after purchasing an additional 41,711 shares during the last quarter. Hedge funds and other institutional investors own 57.99% of the company’s stock.

China Biologic Products Company Profile

China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply